1878 related articles for article (PubMed ID: 20216409)
1. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
2. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.
Napolitano A; Del Dotto P; Petrozzi L; Dell'Agnello G; Bellini G; Gambaccini G; Bonuccelli U
Clin Neuropharmacol; 1999; 22(1):24-9. PubMed ID: 10047930
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.
Baas H; Zehrden F; Selzer R; Kohnen R; Loetsch J; Harder S
Clin Pharmacokinet; 2001; 40(5):383-93. PubMed ID: 11432539
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
7. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M
Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
[TBL] [Abstract][Full Text] [Related]
8. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
9. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
Jorga K; Banken L; Fotteler B; Snell P; Steimer JL
Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
[TBL] [Abstract][Full Text] [Related]
11. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
Blandini F; Nappi G; Fancellu R; Mangiagalli A; Samuele A; Riboldazzi G; Calandrella D; Pacchetti C; Bono G; Martignoni E
J Neural Transm (Vienna); 2003 Aug; 110(8):911-22. PubMed ID: 12898346
[TBL] [Abstract][Full Text] [Related]
12. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F; Lilliu H; Le Pen C
Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
[TBL] [Abstract][Full Text] [Related]
13. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
[TBL] [Abstract][Full Text] [Related]
14. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
15. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
17. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
Davis TL; Roznoski M; Burns RS
Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
[TBL] [Abstract][Full Text] [Related]
18. Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.
Harder S; Baas H
Clin Pharmacol Ther; 1998 Aug; 64(2):183-91. PubMed ID: 9728899
[TBL] [Abstract][Full Text] [Related]
19. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
[TBL] [Abstract][Full Text] [Related]
20. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]